- Home
- CLNE vs ATXS Comparison
CLNE vs ATXS Comparison
Compare CLNE & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLNE
- ATXS
- Stock Information
- Founded
- CLNE 2001
- ATXS 2008
- Country
- CLNE United States
- ATXS United States
- Employees
- CLNE N/A
- ATXS 78
- Industry
- CLNE Natural Gas Distribution
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- CLNE Utilities
- ATXS Health Care
- Exchange
- CLNE Nasdaq
- ATXS Nasdaq
- Market Cap
- CLNE 574.5M
- ATXS 676.1M
- IPO Year
- CLNE 2007
- ATXS 2015
- Fundamental
- Price
- CLNE $2.86
- ATXS $12.12
- Analyst Decision
- CLNE Strong Buy
- ATXS Buy
- Analyst Count
- CLNE 5
- ATXS 7
- Target Price
- CLNE $3.59
- ATXS $30.00
- AVG Volume (30 Days)
- CLNE 1.4M
- ATXS 3.4M
- Earning Date
- CLNE 11-04-2025
- ATXS 11-12-2025
- Dividend Yield
- CLNE N/A
- ATXS N/A
- EPS Growth
- CLNE N/A
- ATXS N/A
- EPS
- CLNE N/A
- ATXS N/A
- Revenue
- CLNE $420,579,000.00
- ATXS N/A
- Revenue This Year
- CLNE $3.49
- ATXS N/A
- Revenue Next Year
- CLNE $1.71
- ATXS N/A
- P/E Ratio
- CLNE N/A
- ATXS N/A
- Revenue Growth
- CLNE 4.08
- ATXS N/A
- 52 Week Low
- CLNE $1.30
- ATXS $3.56
- 52 Week High
- CLNE $3.67
- ATXS $12.52
- Technical
- Relative Strength Index (RSI)
- CLNE 58.54
- ATXS 83.53
- Support Level
- CLNE $2.69
- ATXS $11.83
- Resistance Level
- CLNE $3.00
- ATXS $12.16
- Average True Range (ATR)
- CLNE 0.14
- ATXS 0.42
- MACD
- CLNE 0.01
- ATXS 0.46
- Stochastic Oscillator
- CLNE 69.71
- ATXS 98.87
About CLNE Clean Energy Fuels Corp.
Clean Energy Fuels Corp is a natural gas marketer and retailer operating in the United States and Canada. The company supplies compressed natural gas, liquefied natural gas for the United States (U.S.) and Canadian transportation markets. The majority of revenue is generated within the U.S. and mostly consists of compressed natural gas. The company operates by purchasing natural gas from local utilities; compressing, cooling, or liquefying it at company-owned plants; and selling natural gas products through company-owned or customer-owned fueling stations. The company also builds, operates, and maintains natural gas fueling stations for customers. The company's target markets include heavy-duty trucking, airports, public transit, institutional energy users, and government fleets.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.